Sentinel Lymph Node Biopsy for Recurrent Melanoma: A Multicenter Study
| Autor: | Randall P. Scheri, J. Harrison Howard, April K.S. Salama, Linda M. Youngwirth, Syed Gardezi, Douglas S. Tyler, Yinin Hu, Craig L. Slingluff, Doreen M. Agnese, Alicia M. Terando, Georgia M. Beasley, Kara K. Rossfeld |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
medicine.medical_specialty
Skin Neoplasms Sentinel lymph node Population Disease-Free Survival Article Metastasis 03 medical and health sciences 0302 clinical medicine Biopsy medicine Humans 030212 general & internal medicine education Survival rate Lymph node Melanoma Retrospective Studies education.field_of_study medicine.diagnostic_test business.industry Sentinel Lymph Node Biopsy Retrospective cohort study medicine.disease Neoplastic Cells Circulating Surgery Survival Rate medicine.anatomical_structure Oncology 030220 oncology & carcinogenesis Lymphatic Metastasis Disease Progression Lymph Node Excision Neoplasm Recurrence Local Sentinel Lymph Node business Lymphoscintigraphy |
| Zdroj: | Ann Surg Oncol |
| ISSN: | 1534-4681 |
| Popis: | BACKGROUND. Sentinel lymph node biopsy (SLNB) is routinely performed for primary cutaneous melanomas; however, limited data exist for SLNB after locally recurrent (LR) or in-transit (IT) melanoma. METHODS. Data from three centers performing SLNB for LR/IT melanoma (1997 to the present) were reviewed, with the aim of assessing (1) success rate; (2) SLNB positivity; and (3) prognostic value of SLNB in this population. RESULTS. The study cohort included 107 patients. Management of the primary melanoma included prior SLNB for 56 patients (52%), of whom 10 (18%) were positive and 12 had complete lymph node dissections (CLNDs). In the present study, SLNB was performed for IT disease (48/107, 45%) or LR melanoma (59/107, 55%). A sentinel lymph node (SLN) was removed in 96% (103/107) of cases. Nodes were not removed for four patients due to lymphoscintigraphy failures (2) or nodes not found during surgery (2). SLNB was positive in 41 patients (40%, 95% confidence interval (CI) 31.5-50.5), of whom 35 (88%) had CLND, with 13 (37%) having positive nonsentinel nodes. Median time to disease progression after LR/IT metastasis was 1.4 years (95% CI 0.75–2.0) for patients with a positive SLNB, and 5.9 years (95% CI 1.7–10.2) in SLNB-negative patients (p = 0.18). There was a trend towards improved overall survival for patients with a negative SLNB (p = 0.06). CONCLUSION. SLNB can be successful in patients with LR/IT melanoma, even if prior SLNB was performed. In this population, the rates of SLNB positivity and nonsentinel node metastases were 40% and 37%, respectively. SLNB may guide management and prognosis after LR/IT disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink